West Pharm Svcs Stock Price, News & Analysis

West Pharmaceutical Services, Inc. (NYSE: WST) has declared a first-quarter 2023 dividend of $0.19 per share, payable on February 1, 2023, to shareholders of record by January 25, 2023. The company reported $2.83 billion in net sales for its fiscal year 2021, highlighting its position as a leader in injectable drug administration solutions. West will also participate in the CJS Securities 23rd Annual "New Ideas for the New Year" Conference on January 11, 2023, at 3:05 pm ET.

West Pharmaceutical Services, Inc. (NYSE: WST) announced participation in two key investor conferences. The company will present at the Jefferies London Healthcare Conference on November 15, 2022, at 3:50 PM GMT, and at the Stephens Annual Investment Conference in Nashville, TN, on November 17, 2022, at 2:00 PM CT. Live audio webcasts of both presentations will be available on the company's website, with replays accessible for 90 days post-event. West generated $2.83 billion in net sales in fiscal year 2021 and operates about 50 sites globally, employing approximately 10,000 team members.

West Pharmaceutical Services, Inc. (NYSE: WST) will participate in CPhI Worldwide in Frankfurt, Germany, on November 1, 2022. The company aims to address industry challenges in packaging and containment. Chris Ryan, VP at West, emphasized their collaboration with Corning for advanced solutions in lyophilization and closure integrity. Experts will present on elastomer formulations and container closure systems at scheduled speaking sessions. West, headquartered in Exton, Pennsylvania, reported $2.83 billion in net sales in fiscal year 2021.

West Pharmaceutical Services (WST) reported third-quarter 2022 net sales of $686.9 million, down 2.8%, with organic growth at 4.3%. Reported diluted EPS declined by 31.2% to $1.59, while adjusted diluted EPS fell 1.5% to $2.03. The company updated its full-year net sales guidance to $2.830 billion - $2.840 billion, down from $2.950 billion - $2.975 billion. A quarterly dividend of $0.19, a 5.6% increase, will be paid on November 16, 2022. The CEO anticipates 2023 organic growth exceeding 7%, despite declining COVID-related sales.

West Pharmaceutical Services (NYSE: WST) announced its participation in the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference on October 18, 2022. The company aims to showcase its expertise in drug delivery innovation, focusing on challenges in packaging and containment. Cindy Reiss-Clark, Chief Commercial Officer, highlighted the importance of evolving healthcare needs and technological advancements. West will present several technical sessions, including topics on customized injection profiles and sustainable device selection. In fiscal year 2021, West generated $2.83 billion in net sales.

West Pharmaceutical Services (NYSE: WST) will announce its third-quarter 2022 financial results before market opens on October 27, 2022. Following the announcement, a conference call will be held at 9:00 a.m. Eastern Time to discuss the results and future business expectations. The live audio webcast will be available on the company's Investor Relations website. Interested participants can register in advance to ask questions during the call. A replay will be accessible for 30 days post-event.

West Pharmaceutical Services (NYSE: WST) has been shortlisted for the 2022 Global Generics and Biosimilar Awards, with the winner to be announced on November 2, 2022, at CPhI Worldwide in Frankfurt, Germany. This recognition underscores West's commitment to enhancing patient care through innovative drug delivery solutions. In fiscal year 2021, West achieved net sales of $2.83 billion, reflecting its position as a key player in the injectable solutions market.

West Pharmaceutical Services, traded on NYSE: WST, will participate in the Bank of America Global Healthcare Conference on September 15, 2022, at 1:20 pm BST in London, UK. A live audio webcast will be accessible via the company's website, with a replay available for 90 days post-event. West, a leader in injectable drug solutions, generated $2.83 billion in net sales in 2021 and employs approximately 10,000 team members globally.

West Pharmaceutical Services (NYSE: WST) announced a minority investment in Latch Medical, a Dublin-based innovator in vaccine and biologics delivery technology, on August 11, 2022. This strategic move aims to enhance West's leadership in patient-focused innovations. Latch Medical's Pharma Latch technology offers cost-effective intradermal delivery systems for vaccines, utilizing microneedles for improved dosing. West’s investment aligns with its commitment to drive innovation in healthcare delivery, emphasizing improved patient outcomes.